Oxford BioMedica PLC (OXBDF)

[georgejjl]

ADA–SCID
This is a partner's product, where Oxford Biomedica provide process development and bioprocessing. For more information on Orchard Therapeutics products their website.

Autologous ex-vivo lentiviral gene therapy
Orchard is developing ex-vivo lentiviral gene therapy to restore normal gene function in patients with ADA-SCID

Summary of clinical data to date*
>30 patients treated at UCL and UCLA as of March 2016
100% survival with a follow-up of 2–49 months
Evidence of immune reconstitution
No evidence of insertional mutagenesis
For more information please contact:
[e-mail]

http://orchard-tx.com/programmes/#ada-scid

Good luck and GOD bless,

George